Company intelligence / Profile preview

Fourth State Therapeutics

State College, Pennsylvania, United Statesfourthstate-tx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Fourth State Therapeutics is developing the "Plasma Patch," a cold plasma-based medical device intended to treat chronic and trauma-related wounds by using ionized gas to generate reactive species that destroy pathogens. The technology is currently at the pre-clinical stage, with a provisional patent filed and an estimated 2–5 years before FDA trial initiation. Early research suggests bacteria are less likely to develop resistance compared to antibiotics.

Therapeutic areas: OtherDermatology
Modalities: DeviceCold atmospheric plasma device
Industry: Therapeutic Medical Devices

Partnerships

Penn State University/Invent Penn State programs for entrepreneurship support and research translation

Beyond the preview

Go deeper on Fourth State Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fourth State Therapeutics.

Explore the full profile